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Comparative efficacy of fingolimod vs
natalizumab
A French multicenter observational study
ABSTRACT
Objective: To compare natalizumab and fingolimod on both clinical and MRI outcomes in patients
with relapsing-remitting multiple sclerosis (RRMS) from 27 multiple sclerosis centers participat-
ing in the French follow-up cohort Observatoire of Multiple Sclerosis.
Methods: Patients with RRMS included in the study were aged from 18 to 65 years with an
Expanded Disability Status Scale score of 0–5.5 and an available brain MRI performed within
the year before treatment initiation. The data were collected for 326 patients treated with na-
talizumab and 303 with fingolimod. The statistical analysis was performed using 2 different
methods: logistic regression and propensity scores (inverse probability treatment weighting).
Results: The confounder-adjusted proportion of patients with at least one relapse within the first and
second year of treatment was lower in natalizumab-treated patients compared to the fingolimod group
(21.1% vs 30.4% at first year, p5 0.0092; and 30.9% vs 41.7% at second year, p5 0.0059) and
supported the trend observed in nonadjusted analysis (21.2% vs 27.1% at 1 year, p5 0.0775). Such
statistically significant associations were also observed for gadolinium (Gd)-enhancing lesions and new
T2 lesions at both 1 year (Gd-enhancing lesions: 9.3%vs 29.8%, p, 0.0001; new T2 lesions: 10.6%
vs 29.6%, p , 0.0001) and 2 years (Gd-enhancing lesions: 9.1% vs 22.1%, p 5 0.0025; new T2
lesions: 16.9% vs 34.1%, p 5 0.0010) post treatment initiation.
Conclusion: Taken together, these results suggest the superiority of natalizumab over fingolimod
to prevent relapses and new T2 and Gd-enhancing lesions at 1 and 2 years.
Classification of evidence: This study provides Class IV evidence that for patients with RRMS, na-
talizumab decreases the proportion of patients with at least one relapse within the first year of
treatment compared to fingolimod. Neurology® 2016;86:771–778
GLOSSARY
EDSS 5 Expanded Disability Status Scale; Gd 5 gadolinium; IPTW 5 inverse probability of treatment weighting; JCV 5 JC
virus; MS 5 multiple sclerosis; NS 5 not significant; OFSEP 5 Observatoire of Multiple Sclerosis; OR 5 odds ratio; PML 5
progressive multifocal leukoencephalopathy; RRMS 5 relapsing-remitting multiple sclerosis.
In European countries, natalizumab (Tysabri; Biogen, Cambridge, MA), a monoclonal antibody
targeting VLA4, and fingolimod (Gilenya; Novartis Pharmaceuticals, Basel, Switzerland), a
sphingosine-1 receptor antagonist,1 share the same indication as second-line therapies in highly active
relapsing-remitting multiple sclerosis (RRMS) or as first-line therapy for aggressive and rapidly evolv-
ing disease.
Pivotal trials have shown at 2 years the higher benefits of fingolimod and natalizumab over placebo
on both clinical and MRI disease activity.2–6 In terms of safety, both natalizumab and fingolimod are
generally well-tolerated.2–6 However, natalizumab could be associated with progressive multifocal
leukoencephalopathy (PML), a rare but serious adverse event caused by the JC virus (JCV),7,8 making
its use difficult in predisposed patients. Besides, fingolimod is rarely associated with serious adverse
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events such as opportunistic infection, transient
bradycardia occurring at the treatment initiation,
and basal cell carcinoma.2–4
Considering the benefit/risk ratio of these 2
treatments, it appears useful to compare their effi-
cacy in order to guide the treatment choice for a
given patient. Recent observational studies have
reported inconsistent results on clinical multiple
sclerosis (MS) activity at 1 year (annualized
relapse rate, time to first relapse),9–13 but none
has compared clinical efficacy or MRI disease
activity at 2 years in a large population of patients.
We conducted analyses of both clinical and
MRI outcomes at 1 and 2 years from treatment
initiation in a French national cohort that in-
cludes 629 patients with RRMS treated with
either fingolimod or natalizumab to provide
additional information on their relative efficacy.
METHODS The Observatoire of Multiple Sclerosis
(OFSEP) cohort. We performed a retrospective analysis of data
prospectively collected from 27 French university hospitals involved
in the French OFSEP14 using the European database for multiple
sclerosis software (EDMUS).15 Individual case reports included iden-
tification and demographic data, medical history, biological, electro-
physiologic, and MRI data and treatments, as well as key episodes in
MS course (date of relapses, date of secondary progression, dates of
disability progression). Data were checked for consistency by the
EDMUS software using automatic controls. For the CEFNA study,
data were collected from the OFSEP database through an extraction
of EDMUS on July 11, 2014.
Patients. The following inclusion criteria were defined: patients
with RRMS aged from 18 to 65 years, with an Expanded Disability
Status Scale (EDSS) score ranging between 0 and 5.5, who initiated
either natalizumab or fingolimod between January 1, 2011, and
January 1, 2013 (to avoid a period bias as natalizumab and fingoli-
mod were available in France since May 2007 and December 2011,
respectively), and with an available MRI scan and EDSS assessment
within the year before treatment initiation. Patients with prior
second-line treatment were not included (natalizumab, fingolimod,
cyclophosphamide, mitoxantrone, alemtuzumab, or rituximab).
Clinical baseline characteristics included demographic informa-
tion, disease duration until fingolimod or natalizumab initiation, use
of previous disease-modifying treatment, EDSS level, number of relap-
ses in the preceding year to fingolimod or natalizumab initiation, and
the presence of gadolinium (Gd)–enhancing lesions on baseline MRI
scan. These baseline variables were considered as possible confounding
factors for the further statistical analyses.
Standard protocol approvals, registrations, and patient
consents. The study was conducted in accordance with the
French law relative to clinical noninterventional research. Accord-
ing to the French law on Bioethics (July 29, 1994; August 6,
2004; and July 7, 2011, Public Health Code), the patients’ writ-
ten informed consent was collected. Moreover, data confidenti-
ality was ensured in accordance with the recommendations of the
French commission for data protection (Commission Nationale
Informatique et Liberté, CNIL decision DR-2014-558).
Endpoints. The primary research question was the proportion of
patients with at least one relapse within the first year of treatment. A
relapse was defined by any new or recurrent exacerbation of neuro-
logic symptoms without fever that lasted for at least 24 hours. Sec-
ondary endpoints were the proportion of patients with at least one
relapse at 2 years of treatment, the proportion of patients with a
progression of disability defined by any increase in EDSS score at
12 and 24 months (more or less 3 months) compared to baseline,
the proportion of patients with at least one Gd-enhancing lesion,
and the proportion of patients with at least one new T2 lesion
on MRI scans performed at 12 and 24 months (more or less 3
months) compared to baseline MRI scan.
The results provide Class IV evidence in favor of natalizumab
to prevent relapse within the first year of treatment and are sup-
ported by clinical data at 2 years and by MRI data.
Statistical analyses. The analyses were performed regarding the
initial treatment without considering the treatment’s modifica-
tions. The fingolimod-treated and natalizumab-treated patients
were compared using t tests or Wilcoxon tests for continuous
variables and x2 statistics for categorical variables.
In order to compare the 4 endpoints at 1 year post initiation, the
following possible confounders were taken into consideration: sex,
number of relapses during the year prior to fingolimod or natalizu-
mab treatment onset, presence of Gd-enhancing lesion at baseline
MRI, EDSS baseline score, and hospital. This list was determined
according to medical arguments without statistical selection.
We considered 2 alternative statistical methods. (1) The multi-
variate logistic regression allowed us to obtain confounder-adjusted
odds ratios (ORs). The principle is to model the probability of the
event according to the treatment (fingolimod vs natalizumab) and
the other covariates. To interpret the treatment effect, the covariates’
levels have to be fixed and therefore the treatment effect cannot be
due to covariate imbalance between the 2 treatments. Such a mod-
eling strategy represents the most popular tool to obtain confounder-
adjusted results. (2) The propensity score method based on inverse
probability of treatment weighting (IPTW) allowed us to estimate
confounder-adjusted absolute risks in both fingolimod- and
natalizumab-treated groups. The basic idea is to model how the
probability of receiving fingolimod and natalizumab depends on
the confounders. More precisely, for each patient, the weight was
the ratio between the mean probability to receive her or his treatment
and the individual predicted probability to receive this treatment
according to the 4 covariates previously listed. The individual prob-
abilities were the predicted value obtained by using logistic regression
with hospital as random effect and treatment group as outcome.
All statistical analyses were performed using R software.16
RESULTS Baseline characteristics of fingolimod- and
natalizumab-treated patients: The confounding indication
of natalizumab in patients with active disease. From the
40,965 patients of the OFSEP database, a total of
3,761 patients followed in the 27 university hospitals
participating in this study had at least one prescription
for either fingolimod or natalizumab. Among these pa-
tients, 303 treated with fingolimod and 326 with nata-
lizumab met the inclusion criteria (figure 1).
Baseline demographics and clinical and MRI char-
acteristics of the 629 patients with RRMS included
in the study according to treatment group are presented
in table 1. Of the 629 patients, a total of 539 patients
(83.3% of the fingolimod-treated patients and 87.4%
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of the natalizumab-treated patients) and 458 patients
(75.9% of the fingolimod-treated patients and 69.9%
of the natalizumab-treated patients) had received the
treatment, respectively, for at least 1 and 2 years. There
was a significantly shorter median time from baseline
MRI to natalizumab or fingolimod initiation. The
median time between baseline EDSS assessment and
the treatment initiation was also shorter in natalizumab-
than in fingolimod-treated patients. Both treatments
were mostly initiated in patients previously treated with
at least one first-line DMT. The proportion of
treatment-naive patients was close between the 2 groups
(10.1% for natalizumab vs 13.2% for fingolimod). Pa-
tients with natalizumab had more clinically active MS
than patients with fingolimod, with a tendency towards
a shorter disease duration (8.06 6.1 years vs 9.06 6.8
years, p 5 0.0514) and higher EDSS score (2.8 6 1.3
vs 2.4 6 1.3, p 5 0.0002). In addition, there were
more natalizumab- than fingolimod-treated patients
with at least 1 or 2 relapses in the preceding year of
treatment (p, 0.0001), and at least one active lesion on
baseline MRI scans (p 5 0.0002).
Such confounding by indication required adjust-
ments for the subsequent comparisons of the evolu-
tion of patients between the 2 treatment groups.
Intraindividual evolution of patients during the 2 first
years post initiation in each group: Fingolimod and
natalizumab were both efficient on the disease activity.
Analyses on clinical and MRI endpoints were performed
Figure 1 Patient selection diagram
EDSS 5 Expanded Disability Status Scale; MS 5 multiple sclerosis.
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on different sample sizes due to missing data. The sample
sizes were 629 patients for relapse endpoint at both 1 and
2 years (fingolimod: 303 vs natalizumab: 326), 351 pa-
tients (fingolimod: 143 vs natalizumab: 208) at 1 year,
and 291 (fingolimod: 114 vs natalizumab: 177) at 2 years
for both MRI endpoints and 530 patients (fingolimod:
258 vs natalizumab: 272) at 1 year and 464 (fingolimod:
220 vs natalizumab: 244) at 2 years for EDSS endpoint,
as indicated in figure 1. Fingolimod-treated patients and
natalizumab-treated patients underwent 1-yearMRI scan
with a median of 378 days (quartiles 310 to 470.5) and
346 days (quartiles 323 to 398) post initiation,
respectively (not significant [NS]). EDSS score was
performed with a median of 362 days (quartiles 315 to
401.7) post initiation in fingolimod-treated patients and
357 days (quartiles 329 to 384.2) post initiation in
natalizumab-treated patients (NS).
The initiation of both treatments allowed a better
control of clinical and MRI activities of MS at 1 year.
Indeed, 76.9% of fingolimod-treated patients had had
at least one relapse in the year preceding the treatment
initiation, while only 27.1% of these patients had a
relapse after 1 year of treatment (p , 0.0001) and
37.9% after 2 years (p , 0.0001). In the same way,
89.9% of natalizumab-treated patients had at least one
relapse in the year preceding treatment initiation com-
pared to 21.2% in the year posttreatment (p , 0.0001)
and 31% in the second year (p, 0.0001). Similar results
were obtained for the presence of Gd-enhancing lesions.
In the fingolimod-treated cohort, 42% of the patients
had at least one Gd-enhancing lesion on the
baseline brain MRI compared to 21.0% at 1 year
(p 5 0.0002). This effect was maintained over 2 years
(43.9% vs 19.3%, p 5 0.0001). In the natalizumab-
treated cohort, 57.7% of the patients had at least one
Gd-enhancing lesion at baseline compared to 8.2% at
1 year (p , 0.0001) and this effect was maintained
over 2 years (55.1% vs 8.6%, p, 0.0001). Concern-
ing EDSS scores, a significant decrease after 1 year of
treatment was observed in both groups: from 2.4 to
2.2 for the fingolimod-treated patients (p 5 0.0228)
and from 2.8 to 2.6 for natalizumab-treated patients
(p5 0.0118). This difference was not maintained at 2
years in both groups of patients (from 2.4 to 2.2 for
fingolimod, p 5 0.1843, and from 2.8 to 2.6 for
natalizumab, p 5 0.1451).
Comparisons of endpoints at both 1 and 2 years between
both groups: Fingolimod is less efficient than natalizumab.
Table 2 presents raw comparisons at 1 and 2 years
between the 2 groups. They reveal a trend toward higher
disease activity with increased percentage of relapse in
fingolimod-treated patients as compared to patients
treated with natalizumab (p 5 0.0928) at 1 year. This
tendency was maintained over 2 years (p 5 0.0775).
The MRI outcomes supported this trend at both 1 and
2 years. The proportion of patients with at least one Gd-
enhancing lesion and new T2 lesion was significantly
increased at both 1 (p5 0.0007 and p5 0.0115) and 2
(p 5 0.0130 and p 5 0.0341) years in patients treated
with fingolimod compared to natalizumab.
In order to take into consideration the biases due
to differences between the 2 groups at treatment ini-
tiation, we performed a multivariate logistic regression
Table 1 Baseline demographics, clinical and MRI characteristics of patients with relapsing-remitting multiple sclerosis according to
treatment group
Baseline characteristics All patients Fingolimod Natalizumab p Value
No. of patients considered for analysis 629 303 326
Female, n (%) 479 (76.2) 225 (74.3) 254 (77.9) 0.3036
Age at treatment initiation, y, mean (SD) 37.0 (9.6) 37.2 (9.2) 36.8 (9.9) 0.6487
Disease duration at treatment initiation, y, mean (SD) 8.5 (6.4) 9.0 (6.8) 8.0 (6.1) 0.0514
EDSS score, mean (SD) 2.6 (1.3) 2.4 (1.3) 2.8 (1.3) 0.0002
EDSS score between 3.0 and 5.5, n (%) 288 (45.8) 122 (40.3) 166 (50.9) 0.0082
Previous immunomodulatory treatment,a n (%) 556 (88.4) 263 (86.8) 293 (89.2) 0.2625
Relapse in the preceding year, n (%)
‡1 relapse 526 (83.6) 233 (76.9) 293 (89.9) ,0.0001
‡2 relapses 264 (42.0) 92 (30.4) 172 (52.8) ,0.0001
Gd-enhancing lesions on baseline MRI, n (%) 311 (49.4) 126 (41.6) 185 (56.8) 0.0002
Delay between baseline MRI and initiation, d, median (lower, upper quartiles) 279 (2132; 37) 291 (2161; 243.5) 263.5 (2107; 233) ,0.0001
Delay between baseline EDSS and initiation, d, median (lower; upper quartiles) 212 (264; 0) 231 (289; 0) 0 (236.7; 0) ,0.0001
Abbreviations: EDSS 5 Expanded Disability Status Scale; Gd1 5 gadolinium-enhancing.
The p values refer to t tests or Wilcoxon rank test for continuous variables and x2 tests for categorical variables.
a First-line treatments: interferon-b-1a, interferon-b-1b, glatiramer acetate.
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(figure 2) and computed the confounder-adjusted
proportions of events by propensity score weighting
at 1 and 2 years post initiation (table 3). Altogether,
both methods showed consistent results. Considering
that the characteristics of both groups are identical to
those of the entire cohort (first column of table 1), we
estimated that 30.4% of fingolimod-treated patients
would have at least one relapse within the first year of
treatment vs 21.1% among natalizumab-treated pa-
tients. This significant difference (p 5 0.0092) was
Table 2 Clinical and MRI endpoints (nonadjusted analyses)
Endpoints
1 Year 2 Years
All patients Fingolimod Natalizumab p Value All patients Fingolimod Natalizumab p Value
Clinical
No. of patients considered for relapse analysis 629 303 326 629 303 326
At least one relapse, n (%) 151 (24.0) 82 (27.1) 69 (21.2) 0.0928 216 (34.4) 115 (38.0) 101 (31) 0.0775
No. of patients considered for
EDSS analysis
530 258 272 464 220 244
Disability progression, i.e., decrease in the
EDSS level, n (%)
133 (25.1) 65 (25.2) 68 (25.0) 1.0000 140 (30.2) 65 (29.6) 75 (30.7) 0.8396
MRI
No. of patients considered for
MRI analysis
351 143 208 291 114 177
Gd-enhancing lesion on MRI, n (%) 47 (13.4) 30 (21.0) 7 (8.2) 0.0007 38 (13.1) 22 (19.3) 16 (9.0) 0.0130
At least one new T2 lesion on MRI, n (%) 42 (12.0) 25 (17.5) 17 (8.2) 0.0115 56 (19.2) 29 (25.4) 27 (15.3) 0.0341
Abbreviations: EDSS 5 Expanded Disability Status Scale; Gd1 5 gadolinium-enhancing.
The p values refer to t tests for continuous variables and x2 tests for categorical variables.
Figure 2 Adjusted multivariate logistic regression on clinical and radiologic disease activities according to treatment group
Multivariate analyses were represented as Forest plots at (A) 1 and (B) 2 years of treatment. The covariates used for adjustment were sex, number of
relapses during the year prior to fingolimod or natalizumab treatment onset, presence of Gd-enhancing lesion at baseline MRI, EDSS baseline score,
and university hospital as a random effect. CI 5 confidence interval; EDSS 5 Expanded Disability Status Scale; Fng 5 fingolimod; Gd 5 gadolinium;
Ntz 5 natalizumab; OR 5 odds ratio.
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maintained over 2 years of treatment (41.7% vs
30.9%, p 5 0.0059) and was confirmed using mul-
tivariate logistic regression at 1 and 2 years (figure 2).
We also estimated that more patients in the fingo-
limod group than in the natalizumab group had
Gd-enhancing lesions at 1 (p , 0.0001) and 2 years
(p5 0.0025) or new T2-lesion at both 1 (p, 0.0001)
and 2 years (p 5 0.0010) (table 3). The significant
differences between these confounder-adjusted percen-
tages of lesions at 1 and 2 years were also confirmed
by multivariate logistic regressions (figure 2). The
median time between the initiation of treatment and
the first relapse was comparable in the fingolimod
cohort (138.5 days [quartiles 59.5 to 233]) and in the
natalizumab cohort (135 days [quartiles 83 to 239])
(NS, nonadjusted comparison). Whatever the method
used, no significant difference was observed in terms of
EDSS score progression between the 2 groups of pa-
tients at 1 and 2 years.
These comparisons may suffer some limitations due
to missing data, particularly concerning MRI parame-
ters. Indeed, brain MRIs are not systematically per-
formed before starting fingolimod or natalizumab
and, when available, MRI data are not systematically
registered. To assess this possible bias, we compared
the 184 patients (100 in the fingolimod group and
84 in the natalizumab group) who did not get brain
MRI before treatment initiation and thus were not
included in the study to those for whom MRI was
available (629 patients). As shown in table e-1A (on
the Neurology® Web site at Neurology.org), patients
without MRI were older (p 5 0.0413) and had a lon-
ger disease duration (p 5 0.0138). Moreover, 66.3%
of these patients had a relapse in the year before com-
pared to 83.6% of included patients (p , 0.0001).
However, this bias seemed to affect both cohorts sim-
ilarly (tables e-1B and e-1C). This result suggests that
only the patients with more clinically active disease had
a brain MRI before starting their treatment.
In the same way, some MRI data are also missing
after 1 year of follow-up (160 patients for fingolimod
and 118 for natalizumab). Again, we observed a sig-
nificantly lower percentage of patients with a relapse
at 1 year post-treatment for patients with missing
MRI at 1 year compared to others (table e-2A). This
bias seemed similar between both groups (tables e-2B
and e-2C).
DISCUSSION Observational studies can offer an
attractive alternative when randomized clinical trials
(RCTs) are not available. In the present observational
study, fingolimod seems less efficient than natalizumab
on disease activity as assessed on relapse occurrence, new
gadolinium-enhancing lesions, and new T2 lesions on
brain MRI, after 1 and 2 years of treatment.
RCTs have demonstrated the superiority of nata-
lizumab and fingolimod over placebo to reduce MS
activity.2–6 Our results regarding the proportion of
natalizumab-treated patients free from relapse or Gd-
enhancing lesions were approaching those reported in
the AFFIRM study at 1 and 2 years.5,6 On the con-
trary, fingolimod treatment effect onMS activity seems
lower in our study than in FREEDOMS at both 1 and
2 years.2,4 These differences observed with fingolimod
could be due to the characteristics of the patients
selected in RCTs.
Four recent observational studies have compared
fingolimod and natalizumab, but with inconsistent
results.9–13 In the more recent study,13 based on the
analysis of a multicenter database of patients with
more active MS switched to natalizumab or fingoli-
mod treatments, natalizumab seemed to be more
effective than fingolimod on clinical parameters.
However, in this study, no MRI outcomes were taken
into account in the analysis. Similarly to our work,
the authors found that more severe disease preceding
treatment initiation was associated with a probability
to switch to natalizumab. Hence, in this study13 and
Table 3 Comparisons of endpoints at 1 and 2 years post-treatment initiation according to treatment group: Results from the confounder-
adjusteda proportions obtained by propensity score weighting
Endpoints
1 Year, % 2 Years, %
Fingolimod Natalizumab p Value Fingolimod Natalizumab p Value
Clinical
At least one relapse 30.4 21.1 0.0092 41.7 30.9 0.0059
Disability progression 25.0 26.2 0.7635 27.8 32.0 0.3435
MRI
Gd-enhancing lesion on MRI 29.8 9.3 ,0.0001 22.1 9.1 0.0025
At least one new T2 lesion on MRI 29.6 10.6 ,0.0001 34.1 16.9 0.0010
Abbreviations: EDSS 5 Expanded Disability Status Scale; Gd 5 gadolinium.
a These proportions can be interpreted by considering that the characteristics of both groups are identical to those of the entire cohort (first column of
table 2).
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ours, similar proportions of relapse-free patients with
natalizumab and fingolimod at 1 (81% and 63%) and
2 years (77% vs 52%) were reported. However, on
the contrary we were unable to detect any difference
in terms of EDSS at 1 and 2 years between the 2
treatments but our study was not specifically designed
for this outcome as a primary endpoint. In order to
take into consideration unbalanced characteristics of
the patients at baseline, we used 2 different well-
established statistical methods. First, a multivariate
logistic regression, the most used method in the lit-
erature to assess a treatment effect for binary end-
points, was used. However, its main concern is the
loss of information due to summing up of the results
in a single OR. This ratio represents a relative effect of
treatment and is difficult to interpret for physicians.
Reporting the absolute risks, that can be achieved
using the second statistical method used, IPTW, is
therefore important for a relevant interpretation.17
Moreover adjusted propensity score on identified
confounding factors reduces biases inherent to obser-
vational design and more particularly allocation bias.
The results of both methods were concordant. How-
ever, one cannot exclude the presence of some con-
founding factors of unknown origin, in the contrary
of RCTs which allow the baseline characteristics of 2
groups to be well-balanced. Because the main source
of bias in such nonrandomized studies is the missing
of confounders, one can compare the list we used
with the covariates taken into consideration in the
paper by Kalincik et al.13 Two additional parameters
were considered: evidence of on-treatment MS activ-
ity (relapse, progression of disability, or both) and
prior/baseline disease-modifying therapies. In con-
trast, in our study the presence of Gd-enhancing
lesions on baseline MRI scan was considered.
Our observational study suffers some limitations.
First, we chose MRI data as secondary outcomes but
there was no central read-out, no central quality control,
and no standard acquisition protocol for MRI data. Sec-
ond, differences are also observed when comparing pa-
tients with MRI missing data (not included) and
patients without (included). As expected, patients with
missing data had less active disease than the others, for
whom the disease monitoring was probably more appro-
priate. Another bias is the observational nature of the
study, reflecting clinical practice with data representative
of the MS population. The choice of the treatment not
only depends on the efficacy of the molecule but also
various factors including JCV testing and individual
PML risk, the necessity for recurrent hospitalizations,
or childbearing potential. Considering these weaknesses,
interpretation of the results should be made with caution
until RCTs are available to compare the 2 molecules.
Nevertheless, our observational study provides
Class IV evidence18 for the superiority of natalizumab
over fingolimod to prevent relapse at 1 year. Regard-
ing the absence of RCTs and the heterogeneity of the
literature, these results may provide additional infor-
mation that may help physicians choose second-line
treatment for patients with RRMS.
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